Differing Viewpoints: Does FDA Need More Post-Market Authority?
This article was originally published in The Gray Sheet
Executive SummaryConsumer and patient advocates say FDA needs more post-market authorities from Congress for 510(k)-cleared devices, but manufacturers argue that the agency should be able to work with what it has.
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.